Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic stabilized analogue of human growth hormone-releasing hormone (GHRH). Unlike sermorelin (GHRH 1-29), tesamorelin consists of the full 44-amino acid GHRH sequence conjugated with a trans-3-hexenoic acid group, which stabilizes the molecule and extends its activity.

Tesamorelin is the only FDA-approved GHRH analogue currently available in the United States, approved under the brand name Egrifta (and the updated formulation Egrifta SV) for the treatment of HIV-associated lipodystrophy — specifically, excess visceral abdominal fat accumulation that occurs as a side effect of long-term antiretroviral therapy (ART).

Developed by Theratechnologies, tesamorelin’s approval was supported by two pivotal Phase III randomized controlled trials published in high-impact journals including the New England Journal of Medicine.

How Tesamorelin Works

Tesamorelin is a GHRH receptor agonist — it binds to GHRH receptors on pituitary somatotroph cells and stimulates the synthesis and pulsatile release of growth hormone (GH). GH then signals the liver to produce IGF-1, which mediates downstream anabolic and metabolic effects.

Mechanism relevant to lipodystrophy: HIV-associated lipodystrophy is characterized by excess visceral adiposity driven partly by disordered GH pulsatility. Tesamorelin restores more physiological GH secretion, which promotes lipolysis in visceral adipose tissue — the metabolically active fat depot surrounding the abdominal organs.

Physiological regulation maintained: Like other GHRH analogues, tesamorelin acts through the body’s own GH regulatory system. The hypothalamic somatostatin system remains functional, providing a physiological ceiling on GH elevation and limiting the risk of supraphysiologic GH levels.

FDA Approval and Clinical Evidence

Pivotal Phase III Trials

Two key randomized, double-blind, placebo-controlled trials established tesamorelin’s efficacy:

NEJM 2007 trial (Falutz et al.): In HIV-positive patients with excess visceral fat, tesamorelin 2mg/day for 26 weeks produced:

• ~15% reduction in visceral adipose tissue (VAT) by CT scan — a statistically and clinically significant reduction
• Significant improvements in waist circumference and waist-to-hip ratio
• Improvements in triglycerides and lipid profiles in a subset of patients
• Well tolerated with a manageable side effect profile

Extension and long-term studies: Extended trials confirmed that VAT reduction was maintained with continued treatment. Discontinuation led to partial return of excess fat within weeks, establishing the need for ongoing therapy to maintain benefit.

Secondary and Investigational Findings

NAFLD / liver fat: Studies have found tesamorelin reduces liver fat content and liver enzymes in HIV-positive individuals with suspected non-alcoholic fatty liver disease (NAFLD), suggesting potential hepatic benefits beyond the labeled indication.

Cognitive function: Early research has examined tesamorelin’s potential effects on cognitive function in HIV-positive and aging populations, with some evidence of improved memory — a finding attributed to GH/IGF-1 effects on hippocampal function. Research is ongoing.

Current Clinical Use

FDA-approved indication: Tesamorelin (Egrifta SV, 2mg/day subcutaneous) is indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.

Off-label and compounding contexts: Tesamorelin is also available through U.S. compounding pharmacies for off-label use in other body composition and longevity contexts. Prescribers may use it for adult patients with visceral adiposity unrelated to HIV, though this is outside the FDA-labeled indication.

Dosing and Administration

Approved dosing: 2mg subcutaneous injection once daily, typically in the morning or at consistent daily timing.

Site: Abdomen (rotating injection sites), following standard subcutaneous technique.

Duration: Clinical response (VAT reduction) is typically measurable at 26 weeks. Effects on visceral fat are not maintained after discontinuation — ongoing treatment is required to sustain benefit.

Monitoring: Baseline and periodic IGF-1 measurements are standard to ensure GH stimulation remains within the physiologically appropriate range.

Side Effects

Common:

• Injection site reactions (erythema, pruritus, pain) — the most frequently reported
• Fluid retention / peripheral edema
• Arthralgia (joint pain)
• Myalgia (muscle pain)
• Paresthesia (tingling, numbness in extremities)
• Headache

Metabolic monitoring:

• Glucose: GH has counter-regulatory effects on insulin; monitor fasting glucose and HbA1c, particularly in patients with pre-diabetes or diabetes
• IGF-1: Monitor to ensure values remain within normal age-adjusted ranges

Contraindications

• Active malignancy — GH/IGF-1 promote cell proliferation; contraindicated in active cancer
• Disruption of the hypothalamic-pituitary axis (hypothalamic-pituitary tumors, trauma, surgery, radiation)
• Pregnancy — Category X; tesamorelin may harm the fetus
• Breastfeeding (insufficient safety data)

Medical Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Tesamorelin (Egrifta) is a prescription medication requiring physician oversight. Off-label use outside the FDA-approved indication should only be considered under the supervision of a qualified healthcare provider familiar with GH axis pharmacology.

Related Reading

• Tesamorelin: The GHRH Analogue Guide — Clinical evidence for tesamorelin in lipodystrophy, off-label body composition, and the lean-mass-sparing LIPO-010 data
• GLP-1 and Muscle Loss: Preserving Lean Mass — Tesamorelin in the context of GLP-1 + GH secretagogue combination strategies
• Sermorelin: Growth Hormone Therapy Guide — Compare tesamorelin with sermorelin for GH axis optimization
• Ipamorelin and CJC-1295: The GH Secretagogue Stack Explained — GH secretagogue options and how they differ from tesamorelin
• Peptide Therapy Lab Monitoring Guide — IGF-1 and glucose monitoring essentials for tesamorelin therapy